Member Info for HarChris

The home trial results are arguably the most important of all. Yes the vast majority are ok and are able to 'sweat it out' but that isn't true in the over 70s and over 50s with serious comorbidities. As the age range goes even higher (80s+) the mortality rate gets extremely large. If the home trial results are compelling then certainly there would be no argument over early treatment for the most at risk groups.

If RM sells 700k treatments a year at £700 per treatment
How much is a company worth with revenue of £490m
************************
Let's say super conservatively that it would value sng at £10 a share, £2b mcap. Upside 600% rise, downside 70% fall, with a greater chance of the upside? Compelling risk/reward for sure from this level.

Org, I'm with you up to a point. A few weeks ago some on here were predicting closer to a million treatments a month and imo that's pie in the sky. 100k treatments a month is very possible however we don't even need it to be that high to see your share price target smashed.

50k treatments a month at ~£1k treatment = £50m a month/ £600m a year. Factor in the potential for stockpiling, increased orders in countries where dangerous variants spring up and the potential as a broad spectrum anti viral and the company will be worth £2b+ (£10+).

If you want to be ultra conservative keep a figure of 50k treatments a month across the US and Europe and you might realise you have nothing to worry about.

Sturgeon produces delicious caviar.

Shall we play a game of can you name the 45 sovereign states recognised by the UN that novacyt don't sell into?!

I'll start - Tuvalu!

What Oakleaf? My point was (in theory) starting a few weeks before could have made the difference of a good few months completion time. Just unlucky with timing that's all.

I know I sort of asked this in a roundabout way a few weeks ago, apologies for repeating.

It's frustrating tha we start the p3 just weeks before cases drop off a cliff. If we do an interim analysis on just the UK arm do you think we'll get an rns confirming p3 uk arm completion/ interim analysis in progress?

Matterhorn, it's that time again... expected p3 completion date?!

'We can give you interferons up your arse, up your arse. We can give you interferons up your arse, up your arse. We would let you breathe them deep in but SNG have a patent, we can give you interferons up your arse!'

There are no trades of interest on morningstar, there was no big buyer today and no late reported trades.

I don't think it would affect it. Vaccines reduce the chance of illness leading to hospitalisation in those that go on to catch it but I don't think once you're at the stage that you need oxygen that it makes any difference. Would be more of an issue for the home trial.

God knows where the sp could end up if everyone keeps setting such silly and unattainable targets and deadlines.
*****************
I didn't know this BB could shift a £350m mcap company so much! Positive thoughts guys.

Mikeb, not an easy question to answer. Imo whilst we wait for news about £9. If contract news lands that is both large in number and long in scope (two years+) then we will quickly see new all time highs. Gl!

To be fair to Mac there wasn't a great deal of gloating in the post.

Nah, happy with the number of shares I've got. Will wait it out til home trial results + activ news so ST ups and downs don't make a difference to me now.

I thought Doc was a physician for a while but had also read Catch 22 when I was very young so kept thinking I know that name from somewhere. The penny eventually dropped!

That's a very honest post Woodstock, sorry to hear. Atb

SS, I think it's a bit unfair to say chartists (in this instance Tony) are shouting 'sell', they aren't. They are telling us what is likely to happen to the share price based on no news and low volume. I find it preferable to say, for example, your prediction last week that we would 'smash £2' by Friday.

It appears to me that we have a buyer/buyers keen to build a large holding below 180p. As soon as the share price shoots above 180p the block buying slows to a crawl. Perfect opportunity once again to continue the stake building...